The reduction in the price target from $1.5 to $1 by a Benchmark analyst could lead to a negative perception among investors, potentially causing a short-term decline in Nutex Health's stock price. However, the maintenance of a Buy rating suggests underlying confidence in the company's fundamentals, which may mitigate the negative impact to some extent.